Amyloid β-Protein (1-14)

Description:

The Aβ1-14, Aβ1-15, and Aβ1-16 are elevated in cell media and in CSF in response to γ-secretase inhibitor treatment. The fragments can serve as biomarkers in clinical studies of the effect of such inhibitors. There is evidence that Aβ1-14, Aβ1-15, and Aβ1-16 increase dose-dependently in response to γ-secretase inhibitor treatment while Aβ1-42 levels are unchanged.

Sequence:

DAEFRHDSGYEVHH

General

References

Comments (0)

Name	Amyloid β-Protein (1-14)
Category	Beta-Amyloidand Related Peptides
One Letter Code	DAEFRHDSGYEVHH
Three Letter Code	{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}{Val}{His}{His}
Molecular Weight	1698.730
Application	Alzheimer's Disease

Portelius, Erik, et al. "Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patient." Neurodegenerative Diseases 10.1-4 (2012): 138-140.

Portelius, Erik, et al. "Novel AβIsoforms in Alzheimer's Disease-Their Role in Diagnosis and Treatment." Current pharmaceutical design 17.25 (2011): 2594-2602.

Portelius, Erik, et al. "A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease." Alzheimer's research & therapy 2.2 (2010): 7.